How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion ChapterInvestors Business Daily • 01/31/25
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid PainkillerBarrons • 01/31/25
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.Market Watch • 01/31/25
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in EnglandBusiness Wire • 01/31/25
Vertex Pharmaceuticals Jumps On FDA Approval For Non-Opioid PainkillerInvestors Business Daily • 01/31/25
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute PainBusiness Wire • 01/30/25
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decadesCNBC • 01/30/25
Investors who Lost Money on Vertex Pharmaceuticals Incorporated Should Contact Levi & Korsinsky About an Ongoing Investigation - VRTXAccesswire • 01/30/25
Vertex Pharmaceuticals Incorporated (VRTX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky InvestigatesAccesswire • 01/28/25
Earnings Preview: Vertex Pharmaceuticals (VRTX) Q4 Earnings Expected to DeclineZacks Investment Research • 01/27/25
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10Business Wire • 01/27/25
Investors who lost money on Vertex Pharmaceuticals Incorporated should contact Levi & Korsinsky about an ongoing investigation - VRTXAccesswire • 01/23/25
Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits ResearchGlobeNewsWire • 01/22/25